The Spectranetics Corporation

Philips to acquire The Spectranetics Corporation

Friday, June 30, 2017

Royal Philips, a global leader in health technology, and The Spectranetics Corporation, a U.S.-based global provider of vascular intervention and lead management solutions, have entered into a definitive merger agreement. Pursuant to the agreement, Philips will commence a tender offer to acquire all of the issued and outstanding shares of Spectranetics for $38.50 per share, to be paid in cash upon completion. This represents a 27% premium to Spectranetics closing price on June 27, 2017. The implied enterprise value is approximately EUR 1.9 billion, inclusive of Spectranetics’ cash and debt. The board of directors of Spectranetics has approved the transaction and recommends the offer to its shareholders. The transaction is expected to close in the third quarter of 2017.

[Read More]